Oncological Prognosis of Prostate Lesions by Chemical Exchange Saturation Transfer Magnetic Resonance Imaging (CEST-MRI)

NANot yet recruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

October 31, 2024

Primary Completion Date

June 30, 2027

Study Completion Date

December 31, 2027

Conditions
Suspected Prostate Cancer (increased PSA Level)
Interventions
OTHER

CEST MRI sequence at 3T

"The MRI will be performed at the Clermont Ferrand University Hospital on the 3T research MRI on a Siemens MRI system (MAGNETOM VIDA, Siemens Healthcare, Erlangen, Germany), the emission of the radiofrequency pulses and the reception of the signal will be done using a coil dedicated to the abdo-pelvic region. The images will be analyzed by the radiologist.~MRI is non-irradiating medical imaging. It is practiced according to good practices and the recommendations of the French Society of Radiology.~* Acquisition of morphological T1, T2 sequences for the identification of areas of interest on the pelvic area.~* Acquisition of the CEST MRI sequence (acquisition time 5 min)~* Acquisition of functional sequences, DWI diffusion-weighted images and dynamic DCE sequence after injection of a single dose of non-linear gadolinum.~The imaging report will reveal the presence or absence of tumor lesions in the prostate and their location. Data will then be compared to the histopathological analysis."

Trial Locations (1)

63000

CHU de Clermont-Ferrand, Clermont-Ferrand

All Listed Sponsors
lead

University Hospital, Clermont-Ferrand

OTHER

NCT06669273 - Oncological Prognosis of Prostate Lesions by Chemical Exchange Saturation Transfer Magnetic Resonance Imaging (CEST-MRI) | Biotech Hunter | Biotech Hunter